Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
naxitamab
Anti-GD2 monoclonal antibody (humanised) · anticancer
START
3 mg/kg/day IV days 1,3,5 with GM-CSF (premedicate)
TYPICAL MAX
150 mg/day (3 mg/kg/day)
STOP IF
Severe infusion reaction, PRES, or transverse myelitis
WATCH
Infusion reactions, BP, neuro status, pain control, sodium
CDSCO approvedATC L01FX21
KDIGO 2024 + manufacturer label
- ONSET
- 6min · infusion start
- PEAK
- 1h · end infusion
- t½
- 6d · t½ ~6 d
- DURATION
- 4w · q4w cycle
EXCRETION
Proteolytic catabolism; not excreted intact
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Can cause fetal harm — avoid; effective contraception required.
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Humanised IgG1 monoclonal antibody binding ganglioside GD2 on neuroblastoma cells, triggering complement-dependent and antibody-dependent cellular cytotoxicity.
Indications
Relapsed/refractory high-risk neuroblastoma in bone/bone marrow (with GM-CSF)
Dosing
- Adult
- Pediatric disease: 3 mg/kg/day IV (max 150 mg/day) on days 1, 3, 5 of each cycle with GM-CSF; cycles every 4 weeks.
- Pediatric
- Primary population: 3 mg/kg/day IV days 1,3,5 per cycle (premedicate).
- Renal adjustment
- No specific adjustment (limited data).
- Hepatic adjustment
- No specific adjustment (limited data).
- Geriatric
- Not applicable (paediatric disease).
- Max dose
- 150 mg/day (3 mg/kg/day) on days 1, 3, 5
Pharmacokinetics
Onset
Antitumour effect over cycles
Peak effect
End of infusion (serum)
Duration
Cycle every 4 weeks
Half-life
~5–7 days
Bioavailability
IV 100%
Protein binding
Not applicable (antibody)
Metabolism
Proteolytic catabolism
Excretion
Catabolised (not renally/hepatically excreted intact)
Contraindications
- Severe hypersensitivity to naxitamab
- Caution: requires premedication and resuscitation readiness
Side effects
Common
Severe infusion-related painHypotensionBronchospasm/coughVomitingPyrexiaHypertension
Serious
- Serious infusion reactions/anaphylaxis
- Severe neuropathic pain
- Posterior reversible encephalopathy
- Hypertension
- Transverse myelitis (boxed)
- Severe hyponatraemia
Pregnancy & lactation
Pregnancy
Can cause fetal harm — avoid; effective contraception required.
Lactation
Avoid breastfeeding during and 2 months after therapy.
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Deferiprone
Severe
Database
Clinical effect not specified
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about naxitamab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20